FDA hearing on Amgen's Tavneos will include findings from an independent review on June 12, 2026 Amgen avacopan data manipulation Duke Clinical Research Institute Effectiveness Hearing independent review Injury of liver Serious Tavneos United States Food and Drug Administration withdrawal of approval +
Amgen’s Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume on May 21, 2026 Amgen avacopan bile duct syndrome DILI Dosage Forms DSC3 gene Injury of liver Japan Kissei Labels (device) Resume - Remote control command Tavneos United States Food and Drug Administration update VBDS +
FDA Proposes to Withdraw Approval of Amgen's Tavneos Over Data Manipulation and Safety Issues on April 28, 2026 Amgen ANCA vasculitis Approved data manipulation Injury of liver Tavneos United States Food and Drug Administration Withdraw (activity) +
FDA Requests Additional Safety Data from Eli Lilly on Foundayo for Liver and Heart Risks on April 15, 2026 eli lilly Foundayo Injury of liver obesity pill post-marketing studies Safety Data United States Food and Drug Administration +
FDA Ties Amgen's Tavneos to Eight Deaths and 76 Liver Injury Cases on April 03, 2026 Amgen ANCA vasculitis bile duct syndrome DILI drug safety Injury of liver Tavneos United States Food and Drug Administration +
Intercept Withdraws Ocaliva from US Market After FDA Safety Concerns on September 11, 2025 Clinical Trials concerns Drug withdrawal syndrome Injury of liver Intercept Pharmaceuticals Liver diseases Ocaliva Primary Biliary Cholangitis Safety United States Food and Drug Administration +
Pfizer's Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues on August 05, 2025 Agonist Clinical Trials competition danuglipron Drug Development Glucagon-Like Peptide 1 Injury of liver lotiglipron Obesity PF-06954522 Pfizer +
Pfizer's Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment on April 14, 2025 danuglipron GLP-1 receptor GLP-1/GIP therapies Injury of liver Metabolic Diseases Obesity Pfizer pharmaceutical competition pipeline Weight-Loss Agents +